Regulatory ImpactRegulatory Impact
Insights

Research briefs for regulatory and competitive intelligence teams

Evidence-grounded market and regulatory briefs built for fast scanning, comparison, and strategic follow-up.

Immunology12 min read

The Current IL-4 and IL-13 Product Landscape in 2026

IL-4 and IL-13-targeted therapy has evolved into a broader, more structurally complex market than it was just a few years ago. The field remains concentrated around dupilumab, while selective IL-13 antibodies and a China-based IL-4Rα entrant are building narrower but increasingly important positions.

IL-4IL-13Dupilumab
Read Brief →
Product Landscapes13 min read

The Current CD38 Product Landscape in 2026

CD38 has become one of the most commercially important plasma-cell targets in oncology, with daratumumab defining the category, isatuximab expanding into earlier myeloma settings, and a new wave of biosimilar and immune-mediated disease programs reshaping the next phase.

CD38multiple myelomadaratumumab
Read Brief →
Oncology13 min read

The Current PD-1 and PD-L1 Product Landscape in 2026

PD-1 and PD-L1 checkpoint inhibitors have become a mature oncology class dominated by a small number of high-value franchises, with commercial scale now best understood through annual manufacturer net sales, partial-period run-rate context, label breadth, subcutaneous lifecycle management, and earlier-stage disease expansion.

PD-1PD-L1checkpoint inhibitors
Read Brief →

Stay ahead with new regulatory insights

Get new research briefs on product, target, and competitive landscapes as they publish.

Longevity10 min read

The 2026 Aging and Longevity Product Landscape

A research brief on therapeutic aging science, with emphasis on OSK partial reprogramming, first-in-human development, and the broader translational gap between longevity biology and approvable medical products.

AgingLongevityOSK
Read Brief →
Biopharma Insights14 min read

The Current IL-6 Product Landscape in 2026

IL-6 in 2026 is no longer a single-brand category. The market is defined by a crowded tocilizumab franchise, narrower approved positions for sarilumab, satralizumab, and siltuximab, and a late-stage pipeline that is pushing the pathway into new neurologic and cardiometabolic settings.

IL-6BiologicsBiosimilars
Read Brief →
Research Brief18 min read

The Current IL-23 Product Landscape

Selective IL-23-pathway therapies now span skin, joints, bowel disease, biosimilar-exposed legacy products, and the first oral IL-23 receptor antagonist, creating a more segmented and strategically important market than the earlier psoriasis-only class.

IL-23PsoriasisInflammatory bowel disease
Read Brief →